title: Resonium A - Neonatal Intensive Care Drug Manual
text: |
  Neonatal Intensive Care Drug Manual
  |
  bet | 533/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Resonium A
  Revision Date : 7-1-2021
  |
  Approved: TC, KOH
  |
  Alert
  |
  Insulin-glucose and salbutamol (albuterol) infusions are more effective and safer options for treatment of hyperkalaemia.(1)
  Not for oral administration in neonates
  Effective lowering of serum potassium with Resonium may take hours. The efficiency of potassium exchange is unpredictable and variable.
  Available as sodium or calcium polystyrene sulfonate resins.
  Sodium polystyrene sulfonate is commonly labelled as Kayexalate.
  |
  Indication
  |
  Hyperkalaemia (serum potassium greater than 6.5 mmol/L)
  |
  Action
  |
  Removes potassium from body by exchanging it within the gut for sodium/calcium.
  In vivo, 1 gram of resin exchanges about 1 mmol of potassium.(2)
  |
  Drug type
  |
  Cation exchange resin.
  |
  Trade name
  |
  Resonium A powder for suspension (Sodium polystyrene sulfonate)
  Calcium Resonium Powder for suspension (Calcium polystyrene sulfonate)
  |
  Presentation
  |
  Resonium A powder for suspension – Sodium content is 4.1 mmol/g of Resonium A.(2)
  Calcium Resonium powder for suspension – Calcium content is 1.6-2.4 mmol/g of Resonium.(2)
  |
  |
  |
  | |